Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642079 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
NCT04642079: Completed Phase 3 study, sponsored by Pfizer.
NCT04642079 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 839 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04642079, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
Primary Outcome
Local reactions included redness, swelling and, pain at the injection site, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. One measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \> 0.0 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Pain at the injection site was graded as mild: hurt if gently touched (cohort 1) and did not interfere wit
Interventions
- BIOLOGICAL 20vPnC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2020-12-04 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 3 |
What the finished NCT04642079 record still lists
NCT04642079 is an interventional study that assigns participants to a tested intervention. The registered 839 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which 20vPnC is the first listed.
NCT04642079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04642079 about?
NCT04642079 is a clinical study titled "Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age". This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
What is the current status of trial NCT04642079?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2020-12-04. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT04642079?
The interventions under investigation include: 20vPnC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04642079?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04642079's enrollment target sits among peer trials
839 394th of 2000 higher than 1,607 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI